Haier_Biomedical Achieves Double No. 1 Ranking
Analysis based on 11 articles · First reported May 28, 2026 · Last updated May 28, 2026
The achievement of a double No. 1 ranking by Haier Biomedical in global and overseas sales for life science laboratory equipment is a significant positive for the company. This recognition from Euromonitor International is likely to enhance investor confidence in Haier Biomedical, potentially leading to an increase in its stock price and market valuation. The strong revenue growth in key regions further underscores its expanding global footprint and operational success.
Haier Biomedical has secured a double No. 1 ranking from Euromonitor International for 2025, being recognized as the top Chinese brand in global life science laboratory equipment sales and in overseas sales within the same category. This achievement follows a successful three-phase international expansion, which has resulted in a compound annual growth rate exceeding 20 percent. The company's growth strategy included targeted projects with organizations like UNICEF and the World Health Organization, scaling its distribution network to 160 countries, and embedding full operational capabilities in key regions. Haier Biomedical now operates overseas R&D centers in the United Kingdom, Italy, and Japan. In Q1 2026, the company reported significant revenue growth, including over 50 percent in Germany, Australia, and Canada, and over 100 percent in Eastern Europe, South Asia, and Brazil. Haier Biomedical is also a part of the supply chains for leading pharmaceutical companies in countries such as Switzerland, Germany, Denmark, Italy, Singapore, the United States, Israel, and India, and its Ultra Energy series dominates the United States Energy Star rankings.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard